NCT02681237View on ClinicalTrials.gov

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 29, 2016

Primary Completion Date

January 10, 2022

Study Completion Date

March 25, 2022

Conditions
Ovarian Cancer
Interventions
DRUG

Cediranib

Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.

DRUG

Olaparib

Poly (ADP-ribose) polymerase (PARP) inhibitor.

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University Health Network, Toronto

OTHER